Barameda - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 400,026 | 547,316 | 3,002,578 | 5,172,424 | 2,848,761 | 1,974,930 | 2,103,138 | 2,433,023 |
| Profit before tax | - | - | 1,169,539 | 1,972,845 | 421,933 | 300,666 | 170,434 | 348,282 |
| Net profit | 67,341 | 82,268 | 992,767 | 1,676,117 | 357,372 | 252,847 | 129,370 | 287,045 |
| Equity | 145,284 | 227,553 | 1,150,320 | 2,708,790 | 2,383,357 | 1,812,674 | 1,600,867 | 1,887,912 |
| Liabilities | 64,354 | 80,020 | 875,665 | 629,416 | 400,049 | 211,574 | 326,752 | 191,481 |
| Non-current assets | 9,770 | 7,774 | 24,289 | 18,243 | 61,603 | 49,944 | 39,160 | 27,535 |
| Current assets | 199,868 | 299,799 | 2,001,696 | 3,319,963 | 2,721,803 | 1,974,304 | 1,888,459 | 2,051,858 |
| Total assets | 209,638 | 307,573 | 2,025,985 | 3,338,206 | 2,783,406 | 2,024,248 | 1,927,619 | 2,079,393 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 202,903 | 178,158 | 130,365 |
| Social insurance contributions | - | - | - | - | - | 15,885 | 26,876 | 28,377 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +33.5% | +36.8% | +448.6% | +72.3% | -44.9% | -30.7% | +6.5% | +15.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 32.1% | 26.7% | 49.0% | 50.2% | 12.8% | 12.5% | 6.7% | 13.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 46.4% | 36.2% | 86.3% | 61.9% | 15.0% | 13.9% | 8.1% | 15.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 16.8% | 15.0% | 33.1% | 32.4% | 12.5% | 12.8% | 6.2% | 11.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | 39.0% | 38.1% | 14.8% | 15.2% | 8.1% | 14.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.4 | 0.4 | 0.8 | 0.2 | 0.2 | 0.1 | 0.2 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 200,013 | 273,658 | 1,501,289 | 1,633,380 | 833,776 | 515,204 | 420,628 | 494,849 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Barameda - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-06-17 | 2025-06-17 | 2315.07 |
| 2022-09-16 | 2022-09-19 | 132.65 |
Barameda - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Barameda, UAB, code 303304004, is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the latest financial year, the company generated revenue of €2.43M and net profit of €287.0K, corresponding to a profit margin of 11.8%. Revenue increased by 15.7% year on year and by 23.2% over two years, showing steady top-line expansion. Profitability was more volatile over the period: net profit declined from €252.8K in 2023 to €129.4K in 2024, before recovering strongly in 2025. The balance sheet remained solid, with total assets of €2.08M, equity of €1.89M and liabilities of €191.5K. The equity ratio was 90.8%, and debt-to-equity stood at 0.10, indicating low leverage. Return on equity was 15.2% and return on assets 13.8%, while asset turnover reached 1.17x. Based on the available staffing data, revenue per employee was €608.3K and profit per employee €71.8K in 2025.